Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IO 312

Next Previous
Drug Profile

IO 312

Alternative Names: IO-312

Latest Information Update: 13 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas Health Science Center at Houston; University of Texas Southwestern Medical Center
  • Developer Immune-Onc Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; LILRB4 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 14 Apr 2023 Pharmacodynamics data from a preclinical study in cancer presented at the114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 12 Oct 2022 Preclinical trials in Haematological malignancies in USA (unspecified route) Before October 2022 (Immune-Onc Therapeutics pipeline, October 2022)
  • 06 Apr 2017 Immune-Onc Therapeutics enters into a research agreement with University of Texas Health Science Center at Houston and University of Texas Southwestern Medical Center to discover and develop biotherapeutics to modulate the immune system for Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top